ArticleHeart (British Cardiac Society)2017
Cancer antigen-125 plasma level as a biomarker of new-onset atrial fibrillation in postmenopausal women.
Article in Heart (British Cardiac Society), 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 23 citations in OpenAlex.
- Carbohydrate antigen-125 (CA125): a marker of right ventricular dysfunction and poor prognosis in heart failure with preserved ejection fraction.International journal of cardiology. Heart & vasculature · 2025Article
- CA125 as a Potential Biomarker in Non-Malignant Serous Effusions: Diagnostic and Prognostic Considerations.Journal of clinical medicine · 2025Review
- Predictive Factors of Non-Elevation of Carcinoembryonic Antigen 125 in Acute Heart Failure.Life (Basel, Switzerland) · 2025Article
- Elevated plasma cancer antigen-125 level is associated with increased risk of new-onset atrial fibrillation after acute myocardial infarction.Frontiers in cardiovascular medicine · 2025Article
- Carbohydrate antigen 125 in congestive heart failure: ready for clinical application?Frontiers in oncology · 2023Review
- Factors associated with serum CA125 level in women without ovarian cancer in the United States: a population-based study.BMC cancer · 2022Article
- Evaluation of atrial fibrosis in atrial fibrillation patients with three different methods.Turkish journal of medical sciences · 2022Article
- Endometriosis and cardiovascular disease.European heart journal open · 2022Article
- Plasma carbohydrate antigen-125 for prediction of atrial fibrillation recurrence after radiofrequency catheter ablation.BMC cardiovascular disorders · 2021Article
- Cardiomyopathies and Arrhythmias Induced by Cancer Therapies.Biomedicines · 2020Review
- Adverse cardiac effects of cancer therapies: cardiotoxicity and arrhythmia.Nature reviews. Cardiology · 2020Review
- Interrelationship between oxidative stress, DNA damage and cancer risk in diabetes (Type 2) in Riyadh, KSA.Saudi journal of biological sciences · 2020Article
- CA125 as a Marker of Heart Failure in the Older Women: Population-Based Analysis.Journal of clinical medicine · 2019Article
- Relationship Between Carbohydrate Antigen 125 and Coronary Artery Calcification in Patients without Known Coronary Artery Disease.Medical science monitor : international medical journal of experimental and clinical research · 2018Article
- Cancer antigen-125 and risk of atrial fibrillation: a systematic review and meta-analysis.Heart Asia · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivePlasma cancer antigen (CA)-125 is a tumour marker recently shown to be associated with systolic heart failure and new-onset atrial fibrillation (AF) after myocardial infarction. However, no reports have described the relationship between CA-125 and new-onset AF in healthy postmenopausal women. The aim of the present study was to evaluate the relationship between CA-125 and new-onset AF in postmenopausal women.
methodsBetween 2005 and 2015, 2086 women, including 1012 postmenopausal women, visited our hospital for annual health check-ups. We excluded patients with systolic dysfunction, chronic inflammatory disease, chronic obstructive pulmonary disease, histories of AF or neoplastic diseases. A total of 746 postmenopausal women underwent thorough physical examinations, including those for biomarkers such as brain natriuretic peptide, high-sensitivity C-reactive protein (hs-CRP) and CA-125.
resultsDuring the 10-year observation period, AF was documented in 31 participants (4.2%). The mean age of participants developing AF (75±6 years) was higher than that of those without AF (68±8 years). Participants developing AF showed significantly higher CA-125 (11.4±6.3 U/mL) and hs-CRP (0.10±0.11 mg/dL) levels than did those without AF (7.7±3.2 U/mL, p<0.01; 0.07±0.08 mg/dL, p<0.05). Cox regression analyses revealed ageing (HR 1.3; 95% CI 1.08 to 1.57; p<0.01) and plasma CA-125 levels (HR 1.29; 95% CI 1.10 to 1.51; p=0.02) as independent predictors of AF.
conclusionsHigh CA-125 levels might be associated with new-onset AF in healthy postmenopausal women.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.